222 related articles for article (PubMed ID: 27560197)
1. Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines.
Yu TW; Chueh HY; Tsai CC; Lin CT; Qiu JT
Hum Vaccin Immunother; 2016 Dec; 12(12):3020-3028. PubMed ID: 27560197
[TBL] [Abstract][Full Text] [Related]
2. Novel codon-optimized GM-CSF gene as an adjuvant to enhance the immunity of a DNA vaccine against HIV-1 Gag.
Qiu JT; Chang TC; Lin CT; Chen YM; Li FQ; Soong YK; Lai CH
Vaccine; 2007 Jan; 25(2):253-63. PubMed ID: 16971027
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of a novel vaccine approach using tumor cells that ectopically express a codon-optimized murine GM-CSF in a murine tumor model.
Lin CC; Tsai CC; Lee JM; Fang CH; Chang KS; Wong KK; Lin CT; Qiu JT
Vaccine; 2016 Jan; 34(1):134-41. PubMed ID: 26546261
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte-macrophage colony-stimulating factor, a potent adjuvant for polarization to Th-17 pattern: an experience on HIV-1 vaccine model.
Mahdavi M; Tajik AH; Ebtekar M; Rahimi R; Adibzadeh MM; Moozarmpour HR; Beikverdi MS; Olfat S; Hassan ZM; Choopani M; Kameli M; Hartoonian C
APMIS; 2017 Jun; 125(6):596-603. PubMed ID: 28493367
[TBL] [Abstract][Full Text] [Related]
5. ELISPOT analysis of a new CTL based DNA vaccine for HIV-1 using GM-CSF in DNA prime/peptide boost strategy: GM-CSF induced long-lived memory responses.
Mahdavi M; Ebtekar M; Khorram Khorshid HR; Azadmanesh K; Hartoonian C; Hassan ZM
Immunol Lett; 2011 Oct; 140(1-2):14-20. PubMed ID: 21679728
[TBL] [Abstract][Full Text] [Related]
6. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?
Clive KS; Tyler JA; Clifton GT; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2010 May; 9(5):519-25. PubMed ID: 20450326
[TBL] [Abstract][Full Text] [Related]
7. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in GM-CSF-based cancer immunotherapy.
Yan WL; Shen KY; Tien CY; Chen YA; Liu SJ
Immunotherapy; 2017 Mar; 9(4):347-360. PubMed ID: 28303764
[TBL] [Abstract][Full Text] [Related]
9. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients.
Parmiani G; Castelli C; Pilla L; Santinami M; Colombo MP; Rivoltini L
Ann Oncol; 2007 Feb; 18(2):226-32. PubMed ID: 17116643
[TBL] [Abstract][Full Text] [Related]
10. Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects.
Bowne WB; Wolchok JD; Hawkins WG; Srinivasan R; Gregor P; Blachere NE; Moroi Y; Engelhorn ME; Houghton AN; Lewis JJ
Cytokines Cell Mol Ther; 1999 Dec; 5(4):217-25. PubMed ID: 10850386
[TBL] [Abstract][Full Text] [Related]
11. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.
Spearman P; Kalams S; Elizaga M; Metch B; Chiu YL; Allen M; Weinhold KJ; Ferrari G; Parker SD; McElrath MJ; Frey SE; Fuchs JD; Keefer MC; Lubeck MD; Egan M; Braun R; Eldridge JH; Haynes BF; Corey L;
Vaccine; 2009 Jan; 27(2):243-9. PubMed ID: 18996425
[TBL] [Abstract][Full Text] [Related]
13. Construction and in vitro evaluation of a recombinant live attenuated PRRSV expressing GM-CSF.
Yu L; Zhou Y; Jiang Y; Tong W; Yang S; Gao F; Wang K; Li L; Xia T; Cheng Q; Tong G
Virol J; 2014 Nov; 11():201. PubMed ID: 25420583
[TBL] [Abstract][Full Text] [Related]
14. A novel subunit vaccine co-expressing GM-CSF and PCV2b Cap protein enhances protective immunity against porcine circovirus type 2 in piglets.
Zhang H; Qian P; Peng B; Shi L; Chen H; Li X
Vaccine; 2015 May; 33(21):2449-56. PubMed ID: 25863115
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.
Chang DZ; Lomazow W; Joy Somberg C; Stan R; Perales MA
Hematology; 2004 Jun; 9(3):207-15. PubMed ID: 15204102
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Th1-biased immune efficacy of porcine circovirus type 2 Cap-protein-based subunit vaccine when coadministered with recombinant porcine IL-2 or GM-CSF in mice.
Wang Y; Lu Y; Liu D; Wei Y; Guo L; Wu H; Huang L; Liu J; Liu C
Appl Microbiol Biotechnol; 2015 Feb; 99(3):1155-63. PubMed ID: 25487886
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes.
Ahlers JD; Dunlop N; Alling DW; Nara PL; Berzofsky JA
J Immunol; 1997 Apr; 158(8):3947-58. PubMed ID: 9103465
[TBL] [Abstract][Full Text] [Related]
18. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun.
Bagley KC; Lewis GK; Fouts TR
Clin Vaccine Immunol; 2011 Jun; 18(6):922-30. PubMed ID: 21508173
[TBL] [Abstract][Full Text] [Related]
20. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
